The MD Magazine Atherosclerosis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.


FDA Approves Once-Monthly Injections that lower LDL Cholesterol
Praluent can help patients with clinical ASCVD or HeFH
Robert A. Gabbay, MD, PhD, and Scott Solomon, MD, define metabolic syndrome and, based on current evidence regarding its manifestation, discuss how healthcare professionals currently manage patients with the condition to reduce their risk for cardiovascular events.
Pitavastatin is superior to pravastatin in reducing LDL in patients with HIV.
Certain conditions are linked to multiple sclerosis disease progression.
Richard A. Chazal, MD, who was the ACC president at the time of the of the most recent ACC conference, revealed which presented studies he believes could change medical practice in the near future. He also discussed how low LDL cholesterol level guidelines will go.
Breakthrough status for a new drug to treat familial hypercholesterolemia.
Excitement has been surrounding PCSK9 inhibitors due to high efficacy in lowering cholesterol. However, two reports in 2015 found that two of these drugs (evolocumab and alirocumab) were linked to cognitive issues. A phase 3 trial at ACC 2017 set out to find if that's actually the case.
A synthetic version of "good" cholesterol failed to clear blocked arteries.
Jay Edelberg, MD, PhD, discusses the alirocumab phase 3 trial results at ACC 2017. “The results demonstrated that genetics really teach us a lot,” he said, noting that the majority of high-risk patients were able to achieve their treatment goals with just the 75 mg dose.

Most Popular


$vacMongoViewPlus$ $vAR$